Track market-moving stories before they get noisy

Stryker (SYK - Free Report) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.

The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on October 29. On the other hand, if they miss, the stock may move lower.

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.

Zacks Consensus EstimateThis medical device maker is expected to post quarterly earnings of $3.56 per share in its upcoming report, which represents a year-over-year change of +11.6%.

Revenues are expected to be $6.58 billion, up 8.6% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 0.8% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for Stryker?For Stryker, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -0.44%.

On the other hand, the stock currently carries a Zacks Rank of #4.

So, this combination makes it difficult to conclusively predict that Stryker will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that Stryker would post earnings of $3.46 per share when it actually produced earnings of $3.69, delivering a surprise of +6.65%.

Over the last four quarters, the company has beaten consensus EPS estimates three times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Stryker doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

An Industry Player's Expected ResultsAnother stock from the Zacks Medical - Products industry, Boston Scientific (BSX - Free Report) , is soon expected to post earnings of $0.76 per share for the quarter ended September 2026. This estimate indicates a year-over-year change of +1.3%. Revenues for the quarter are expected to be $5.17 billion, up 2.1% from the year-ago quarter.

The consensus EPS estimate for Boston Scientific has been revised 0.5% lower over the last 30 days to the current level. However, a lower Most Accurate Estimate has resulted in an Earnings ESP of -1.44%.

When combined with a Zacks Rank of #4 (Sell), this Earnings ESP makes it difficult to conclusively predict that Boston Scientific will beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates three times.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

Key Takeaways Stryker enters soft-tissue robotics with a $400 million investment and exclusive U.S. Versius sales rights.The deal gives Stryker an exclusive option to acquire CMR Surgical and expand its robotic surgery portfolio.Versius' modular design offers operating room flexibility, while the investment supports global expansion. Stryker (SYK - Free Report) recently announced a strategic alliance with CMR Surgical, a global robotics company, to advance robotic-assisted surgery through an approximately $400 million (£300 million) preferred equity investment. The agreement grants Stryker an exclusive option to acquire the remaining equity of CMR Surgical in the future and makes it the exclusive U.S. sales agent for CMR Surgical’s Versius robotic surgery portfolio.

The move represents a strategic expansion into soft-tissue robotic-assisted surgery, combining CMR Surgical's established technology and clinical experience with Stryker's commercial reach and relationships with healthcare providers.

SYK Is Expanding Into Soft-Tissue Robotic SurgeryThe alliance provides Stryker with an opportunity to enter a growing segment of surgical robotics through an established platform. CMR Surgical’s second-generation Versius robotic platform has clinical experience globally and supports a broad range of soft-tissue surgical applications.

Designed for real-world operating environments, the Versius robot features a modular architecture intended to provide flexibility across surgical specialties, operating rooms and sites of care. Its configuration allows hospitals and ambulatory surgery centers (ASCs) to integrate robotic-assisted surgery into existing operating room workflows while maintaining operational flexibility.

According to Andy Pierce, group president of MedSurg and Neurotechnology at Stryker, soft-tissue robotics represents a natural extension of the company’s strengths in endoscopy, visualization and enabling technologies. The collaboration is expected to support broader adoption of robotic-assisted surgery across hospitals and ASCs.

Investment Supports Innovation and Global ExpansionStryker's approximately $400 million preferred equity investment is intended to support further product innovation and the global commercialization of Versius. Under the agreement, CMR Surgical will continue to lead product development and commercialization outside the United States, while Stryker will focus on U.S. sales. This arrangement allows both companies to contribute their respective strengths while pursuing broader international adoption.

The exclusive acquisition option is another important component of the agreement. It gives Stryker the opportunity to acquire 100% of CMR Surgical's outstanding equity in the future, subject to the agreement's terms. If exercised, the option could provide Stryker with greater control over the Versius platform and its long-term development.

Strategic ImplicationsThe alliance strengthens Stryker's position in surgical robotics, a market in which established medical technology companies are competing to provide more comprehensive solutions for surgeons and healthcare systems. While its Mako robotic platform has established a strong presence in orthopedic surgery, the addition of the Versius portfolio offers an opportunity to diversify into the growing soft-tissue robotics market.

For CMR Surgical, Stryker's investment and U.S. commercial support could improve its ability to compete against larger, established robotics companies. Versius' modular design may appeal to providers seeking flexibility in operating room configuration and a practical pathway to expanding robotic surgery. Commercial success will depend on clinical adoption, procedure volumes, hospital purchasing decisions, and the ability to demonstrate operational and economic benefits.

Peers in the Surgical Robotics SpaceMedtech leaders and specialized robotics companies like Intuitive Surgical (ISRG - Free Report) , Medtronic (MDT - Free Report) and Johnson & Johnson (JNJ - Free Report) are expanding their robotic platforms to improve surgical precision, workflow efficiency and access to minimally invasive procedures.

Intuitive Surgical maintains a strong position in robotic-assisted surgery through its da Vinci surgical systems. Its latest generation, the da Vinci 5 platform, incorporates more than 150 design innovations, including Force Feedback technology, enhanced 3D visualization, improved ergonomics and advanced data analytics. The platform is designed to improve surgeon control, streamline operating room workflows and support personalized surgical training. Its established installed base and recurring revenues from instruments, accessories and services provide a strong competitive advantage. Intuitive Surgical also offers the da Vinci SP system for single-port surgical procedures, expanding its minimally invasive surgery portfolio.

Medtronic is another major competitor through its Hugo robotic-assisted surgery system, which targets soft-tissue procedures. The modular platform combines wristed instruments, 3D visualization and digital capabilities supported by the Touch Surgery ecosystem. In December 2025, Medtronic received FDA clearance for Hugo in urologic procedures in the United States. The company pursued expanded indications in general and gynecologic surgery. Its September 2026 FDA clearance for the LigaSure RAS Maryland instrument further strengthens the platform’s surgical capabilities.

Johnson & Johnson is advancing its surgical robotics strategy through its Ottava robotic surgical system, alongside its broader Ethicon surgical instruments and technologies business. In July 2026, the company received FDA De Novo authorization for multiple upper-abdominal general surgery procedures. OTTAVA features a table-integrated robotic architecture designed to optimize operating room space, facilitate surgical team access and improve procedural workflows. Johnson & Johnson is seeking to combine robotic capabilities with its surgical portfolio and global relationships with healthcare providers to support greater adoption of robotic-assisted procedures across healthcare settings.

NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Stryker Corp. (“Stryker” or the “Company”) (NYSE: SYK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Stryker and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 8, 2026, Stryker’s CEO disclosed at the Wells Fargo Healthcare Conference that a manufacturing problem affecting inventory supply in its peripheral vascular business, which management had previously indicated was expected to resolve during the third quarter of 2026, in fact remained unresolved and was now expected to persist into the fourth quarter. 

On this news, Stryker’s stock price fell $26.70 per share, or 8.81%, to close at $276.43 per share on September 8, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

Portage, Michigan, Oct. 06, 2026 (GLOBE NEWSWIRE) --

Kevin Lobo to transition to Executive Chair of the Board of DirectorsCurrent President and COO Spencer Stiles appointed Chief Executive OfficerLeadership transition effective January 1, 2027

Stryker (NYSE:SYK), a global leader in medical technologies, today announced that as part of a planned succession process, Kevin Lobo will transition to the role of Executive Chair of the Board of Directors, effective January 1, 2027. Spencer Stiles, currently President and Chief Operating Officer of Stryker, will succeed Lobo as Chief Executive Officer and will also be appointed as a member of the company’s Board at that time.

Lobo has led a distinguished career at Stryker spanning more than 15 years. He joined the company in 2011 as Group President, became Chief Executive Officer in October 2012 and was appointed Chair of the Board in July 2014. During his transformative 14-year tenure as CEO, Lobo significantly expanded Stryker’s portfolio and global presence and tripled annual net sales from $8.7 billion in 2012 to more than $26 billion in 2026. Under his leadership, Stryker has completed more than 60 acquisitions, including Mako, which combined pioneering robotic-arm-assisted technology with Stryker’s joint-reconstruction expertise to transform the orthopaedic industry, strengthening Stryker’s position as a diversified global leader in medical technologies. Lobo also helped shape the culture that defines Stryker today, establishing its mission to make healthcare better together with its customers, while advancing a specialized business operating model that has supported the company’s distinctive performance and growth.

“Serving as CEO of Stryker has been an incredible honor, and I am proud of all that our teams have accomplished together on behalf of our customers and the patients they serve,” said Lobo. “The Board and I have worked closely on a succession plan, and with our strong foundation in place, now is the right time for this leadership transition. Having worked alongside Spencer for many years, I have seen firsthand the qualities that define his leadership: his ability to set a clear direction, inspire people and translate strategy into strong execution. He understands what makes Stryker unique and has the judgment, experience and commitment to our mission and values to build on our momentum and lead the company forward. I look forward to working with Spencer to ensure a smooth transition and to continuing to support Stryker as Executive Chair of the Board.”

“I am honored to be named Stryker’s next CEO and grateful to the Board and Kevin for their trust in me,” said Stiles. “I have a deep appreciation for our people, our culture and the customer relationships that drive our innovation and growth. Kevin has built an extraordinary legacy and a strong foundation for the future, which I am excited to build upon as we continue executing our strategy, driving growth and advancing our mission to make healthcare better.”

Stiles is a strategic, growth-oriented and people-focused leader with a proven record of execution throughout his distinguished career at Stryker spanning nearly three decades. Since joining the company’s Endoscopy business in 1999, he has held leadership roles across nearly every Stryker business, spanning Orthopaedics, MedSurg and Neurotechnology. Before becoming President and Chief Operating Officer in January 2026, Stiles served as Group President, Orthopaedics, leading the company’s Joint Replacement and Trauma & Extremities businesses and its Digital, Robotics and Enabling Technologies organization, with additional responsibility for international regions and Stryker’s enterprise mergers and acquisitions strategy. He has also led significant portfolio initiatives, including the acquisition of Wright Medical, which enhanced Stryker’s global market position in trauma and extremities, and the separation of the company’s spinal implants business.

“This announcement is the culmination of a comprehensive, long-term succession planning process,” said Sheri McCoy, Lead Independent Director of Stryker’s Board of Directors. “Spencer is a proven leader with strategic perspective and the ability to unite teams around shared priorities. The Board is confident that he is the right leader to build upon Stryker’s momentum and guide the company’s next chapter. On behalf of the Board, I also want to recognize Kevin for his exceptional leadership and service over his tenure as CEO. Kevin has positioned Stryker to enter this transition from a place of strength. With a mission-driven culture, clear strategic direction and a strong leadership team, Stryker is poised to capture the significant opportunities ahead. We are fortunate that we will continue to benefit from his experience and perspectives as Executive Chair.”

Forward-Looking Statements
This press release contains forward-looking statements subject to the safe harbor protection provided by Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements regarding the Company’s strategy, growth prospects and opportunities, and the Company’s ability to execute on its priorities during and following the transition. These forward-looking statements involve various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such risks and uncertainties include, but are not limited to: risks associated with the transition of executive leadership and the ability of Mr. Stiles and the Company’s executive team to execute on the Company’s strategy and business plans; the Company’s ability to retain key personnel during and after the transition; and other risks listed or described from time to time in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that affect the likelihood that actual results will differ from those contained in the forward-looking statements, except to the extent required by law.

About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.

Contacts
For investor inquiries:
Nick Mead, Vice President, Investor Relations at 269-385-2600 or [email protected]   

For media inquiries:
Kim Montagnino, Vice President, Chief Communications Officer at 269-385-2600 or [email protected]

Spencer Stiles Infographic Kevin Lobo Infographic

SAN FRANCISCO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- On September 8, 2026, investors in Stryker Corporation (NYSE: SYK) saw the price of their shares fall $26.70 (-8.8%) after the company’s CFO revealed that a previously-thought resolved manufacturing issue persists. The move lower wiped out over $10 billion of Stryker’s market capitalization.

The developments have prompted national shareholders rights firm Hagens Berman to open an investigation into whether Stryker was sufficiently transparent about the issue and, if not, whether the company may have violated the federal securities laws.

The firm encourages Stryker investors who suffered substantial losses to submit your losses now. Persons with knowledge who may be able to assist the investigation are invited to contact the firm’s attorneys.

Visit: www.hbsslaw.com/syk
Direct Contact Email: [email protected]
Firm Telephone: 844-916-0895

Stryker Corporation (SYK) Investigation:

The investigation is focused on the propriety of Stryker’s disclosures about its Inari Medical operations and growth prospects. Stryker acquired Inari in February 2025 to supplement Stryker’s Peripheral Vascular reporting unit.

On July 30, 2026, Stryker reported its Q2 2026 results and said, without providing details, that it faced supply disruptions in the Peripheral Vascular unit and that the disruption resulted in “a meaningful backorder situation with lost sales in the quarter.” Nonetheless, management assured investors that “[w]e have addressed the issue and backorder should reach a manageable level by the end of Q3.”

During the related earnings call that day, an analyst asked for some color on the disruption and what exactly happened. CEO Kevin Lobo said, “I’m not going to get into the details of what it was, but let’s just say it did cause a significant backorder specific to one plant in the Inari business,” and “[t]he backorder is pretty elevated right now.”

In response, the market sent the price of Stryker shares down $22.34 (-6.4%) the next day.

Then, during the September 8, 2026 Wells Fargo Healthcare Conference, CFO Preston Wells further described the manufacturing issue as “not allowing us to reach a full supply of inventory at all of our customers[]” and “quite frankly, not allowing us to go out and really win new business.”

Most concerning was his revelation that, in contrast to previous assurances, the problem “is continuing into the third quarter and will certainly continue – we expect it to continue a little bit into the fourth quarter as well.”

The market negatively reacted again, sending the price of Stryker shares sharply lower that day.

“We’re focused on when Stryker knew its Peripheral Vascular manufacturing problem hadn’t been resolved and would persist beyond Q3,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

If you invested in Stryker and have substantial losses, or have knowledge that will assist the firm’s investigation, submit your losses now »

Whistleblowers: Persons with non-public information regarding Stryker should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman
Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact: Hagens Berman, Reed Kathrein, 715 Hearst Avenue, Suite 300, Berkeley, CA 94710, 844-916-0895, [email protected]

New additions advance surgical planning, implant flexibility and connected care across Stryker's Foot & Ankle portfolio

Stryker is launching Prophecy® Surgical Planning for the Incompass™ Total Ankle System and introducing Hoffmann®LRF smartHEX™ at the 2026 American Orthopaedic Foot & Ankle Society Annual Meeting in Seattle. Prophecy® Surgical Planning, which has supported patient-specific planning for more than 100,000 ankle cases over 14 years, is now available with the Incompass™ Total Ankle System, giving surgeons access to 3D visualization and both resect-through and pin-through fixation options within a single connected platform. Hoffmann LRF smartHEX expands Stryker's limb reconstruction portfolio with new rings, struts and frame components along with a mobile app and reimagined planning software designed to enhance frame versatility and support connected care. , /PRNewswire/ -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today that it will showcase new advancements across its Foot & Ankle portfolio at the 2026 American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting in Seattle, including the launch of Prophecy Surgical Planning for the Incompass Total Ankle System and the introduction of Hoffmann LRF smartHEX.

Stryker is launching Prophecy® Surgical Planning for the Incompass™ Total Ankle System and introducing Hoffmann® LRF smartHEX™ at the 2026 American Orthopaedic Foot & Ankle Society Annual Meeting in Seattle. Prophecy has established itself as an important surgical planning tool in ankle surgery, processing more than 100,0001 cases over the past 14 years. Now available with Incompass, Stryker's comprehensive total ankle replacement system, Prophecy enables surgeons to leverage this depth of experience through patient-specific surgical planning, enhanced 3D planning tools, and both resect-through and pin-through fixation options. The integration of these two products further reflects Stryker's commitment to delivering technology-enabled solutions.

"We've seen incredible customer adoption and feedback around Prophecy, and we're excited to extend that offering to Incompass," said Adam Jacobs, vice president and general manager of Stryker's Foot & Ankle business. "By bringing Prophecy to Incompass, we're combining the power of patient-specific planning with our newest total ankle system, helping surgeons make more informed decisions before they ever enter the operating room."

The Incompass Total Ankle System was created using insights generated through Prophecy and SOMA (Stryker Orthopaedic Modeling and Analytics), incorporating real-world anatomy and surgical planning into the implant design. The addition of Prophecy Surgical Planning further strengthens the connection between preoperative planning and implant selection, enabling surgeons to make more informed decisions.

Expanding beyond total ankle replacement, Stryker will also introduce Hoffmann LRF smartHEX, the newest advancement in its limb reconstruction portfolio. The platform combines expanded frame options, mobile guidance and updated planning software designed to support complex deformity correction. Through the mobile application, smartHEX creates a connection between patients and their surgeon-prescribed correction plan, bringing patient guidance, surgeon planning and correction capabilities together throughout treatment.

"AOFAS gives us an important opportunity to demonstrate how Stryker is building on decades of foot and ankle experience, customer insight and data," said Jacobs. "By bringing Prophecy Surgical Planning to Incompass and introducing Hoffmann LRF smartHEX, we are continuing to connect planning, implants and reconstruction technologies in ways that give surgeons more flexibility across the continuum of foot and ankle care."

Attendees can experience both technologies and Stryker's full Foot & Ankle portfolio through exhibit and educational programming at AOFAS 2026, booth #601.

For more information about Stryker's complete Foot & Ankle portfolio, visit www.stryker.com.

About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.

Media contact
Stryker
Jenny Braga
Senior Director, External Affairs
[email protected]

Based on internal data. SOURCE Stryker

Key Takeaways Stryker completed the first hip arthroscopy using SportSuite Vision on Apple Vision Pro at Duke Health.SYK's app is the first FDA-authorized surgical application for intraoperative use with Apple Vision Pro.Stryker's SportSuite Vision could support a more connected digital operating room in Sports Medicine. Stryker (SYK - Free Report) recently announced the successful completion of the first hip arthroscopy procedure using its SportSuite Vision application on Apple Vision Pro at Duke Health. The milestone follows the FDA's De Novo authorization for the application in July, making it the first surgical application approved for intraoperative use with Apple's mixed reality headset.

From an investor's perspective, the development reinforces Stryker's push to strengthen its digital surgery portfolio and expand innovation across its Sports Medicine business. Although the launch is unlikely to materially affect near-term revenue, it could enhance the company's competitive position, support wider adoption of its surgical ecosystem and create long-term growth opportunities as hospitals increasingly embrace advanced operating room technologies.

Likely Trend of SYK Stock Following the NewsFollowing the announcement, shares of SYK traded flat on Wednesday. Year to date, shares of the company have lost 11.1% compared with the industry’s 17% decline. However, the S&P 500 has risen 10.9% in the same timeframe.

In the long run, SportSuite Vision could strengthen Stryker's competitive moat by expanding its digital surgery ecosystem and making its Sports Medicine portfolio more integral to hospital workflows. As the first FDA-authorized intraoperative application for Apple Vision Pro, the platform gives Stryker an early-mover advantage in spatial computing, which could drive greater adoption at academic medical centers and high-volume orthopedic hospitals. Over time, this ecosystem approach may encourage repeat software and hardware purchases, deepen customer loyalty and support sustained growth across the company's surgical technologies business.

SYK currently has a market capitalization of $121.8 billion.

Image Source: Zacks Investment Research

Details of the NewsFollowing the FDA's De Novo authorization on July 17, SportSuite Vision became the first application cleared for intraoperative use with Apple Vision Pro, establishing a new regulatory benchmark for spatial computing in the operating room. The first live use of the technology took place during a hip arthroscopy at Duke Health, where orthopedic surgeon Chad Mather III performed the procedure, demonstrating the platform's transition from regulatory clearance to real-world clinical adoption at a nationally recognized academic medical center.

SportSuite Vision is designed for femoroacetabular impingement and labral repair hip arthroscopy procedures, combining arthroscopic video, HipCheck, HipMap FAI Analysis and CT imaging within a customizable spatial computing environment. The software allows surgeons to view these digital tools alongside the physical operating room through a video see-through augmented reality headset, while operating room staff continue using traditional monitors. According to Stryker, this integrated approach represents another step toward building a more connected digital operating room across its Sports Medicine franchise.

Benefits for SurgeonsThe new platform is designed to make hip arthroscopy more intuitive by keeping critical clinical information within the surgeon's line of sight throughout the procedure. Instead of repeatedly looking toward multiple monitors positioned around the operating room, surgeons can arrange key data based on their preferred workflow and access it within the sterile field. This setup can create a more comfortable and ergonomic operating environment, reduce unnecessary head movement and help streamline procedures by keeping essential information readily visible during surgery.

Industry Prospects Favoring the MarketGoing by the data provided by Research and Markets, the digital surgery technologies market size is expected to see exponential growth in the next few years. The market was valued at $1.48 billion in 2025 and is likely to reach beyond $5.36 billion by 2030 at a CAGR of 28.3%.

Growth in the forecast period can be attributed to the expansion of AI and big data in surgical workflows, growth of extended reality applications in surgery, increased adoption of software-based surgical navigation, development of advanced robotics control software and installation and maintenance services for digital surgical systems.

Other NewsRecently, SYK announced a definitive agreement to acquire ZuriMED, developer of the FiberLocker System, a commercialized technology designed for rotator cuff augmentation with increased biomechanical strength. The acquisition is aimed at strengthening Stryker’s shoulder portfolio and expanding its ability to support specialists across the continuum of shoulder care.

Per Stryker management, ZuriMED’s technology addresses an important unmet need for shoulder care.

SYK’s Zacks Rank & Key PicksCurrently, SYK has a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and The Cooper Companies (COO - Free Report) .

Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.

The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.

COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.

 | Source: Stryker Corporation

Portage, Mich., USA, Aug. 31, 2026 (GLOBE NEWSWIRE) --

Stryker has signed a definitive agreement to acquire ZuriMED, developer of the FiberLocker System, a commercialized technology that provides a novel approach for rotator cuff augmentation designed for increased biomechanical strength.The acquisition strengthens Stryker’s shoulder portfolio, enhancing its ability to support specialists across the continuum of care.The FiberLocker System is a soft tissue augmentation technology designed to reduce the occurrence of a key clinical failure mode in rotator cuff repair, one of the fastest-growing segments in sports medicine.
Stryker (NYSE:SYK), a global leader in medical technologies, announced it has signed a definitive agreement to acquire ZuriMED, a privately held company and developer of the FiberLocker® System. This commercialized technology provides a novel approach for rotator cuff augmentation with increased biomechanical strength to address a key clinical failure mode in rotator cuff repair.

Rotator cuff augmentation is one of the fastest-growing areas in sports medicine and represents a significant opportunity within shoulder care.1 The acquisition will enhance Stryker’s ability to support shoulder specialists across both sports medicine and arthroplasty, strengthening its portfolio in rotator cuff augmentation.

“ZuriMED has developed a differentiated technology that addresses an important clinical need within shoulder care,” said Andy Pierce, Group President, MedSurg and Neurotechnology, Stryker. “We are excited about the opportunity to add the FiberLocker System to Stryker’s portfolio. This acquisition reflects our continued commitment to advancing innovation and improving patient outcomes.”

This transaction is subject to customary closing conditions. Stryker and ZuriMED will continue to operate as separate entities and proceed with business as usual until the transaction closes.

About Stryker        
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.

Contacts
For investor inquiries:
Nick Mead
Vice President, Investor Relations
[email protected]

For media inquiries:
Kim Montagnino
Vice President, Chief Communications Officer
[email protected]

References

Mordor Intelligence. Rotator Cuff Treatment Market Size and Share Analysis – Growth, Trends, and Forecasts (2026–2031). Mordor Intelligence report.

BNP Paribas cut its stake in shares of Stryker Corporation (NYSE:SYK – Free Report) by 90.2% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,713 shares of the medical technology company’s stock after selling 15,825 shares during the period. BNP Paribas’ holdings in Stryker were worth $539,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. VanderPol Investments L.L.C. boosted its holdings in shares of Stryker by 1.4% during the fourth quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock worth $732,000 after purchasing an additional 28 shares during the period. KCM Investment Advisors LLC increased its stake in Stryker by 1.5% in the 4th quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock valued at $653,000 after buying an additional 28 shares during the period. Rossby Financial LCC increased its stake in Stryker by 6.6% in the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock valued at $159,000 after buying an additional 28 shares during the period. Tcfg Wealth Management LLC lifted its position in Stryker by 2.7% in the 3rd quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock worth $403,000 after buying an additional 29 shares in the last quarter. Finally, ICW Investment Advisors LLC boosted its stake in shares of Stryker by 0.6% during the 4th quarter. ICW Investment Advisors LLC now owns 5,096 shares of the medical technology company’s stock valued at $1,791,000 after buying an additional 30 shares during the period. 77.09% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In SYK has been the subject of several recent research reports. Sanford C. Bernstein set a $410.00 price objective on Stryker in a report on Friday, May 1st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Stryker in a research note on Friday, July 31st. Wolfe Research lowered Stryker from an “outperform” rating to a “peer perform” rating in a report on Thursday, August 13th. JPMorgan Chase & Co. lowered their price target on Stryker from $400.00 to $350.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Finally, The Goldman Sachs Group restated a “neutral” rating and issued a $361.00 price objective on shares of Stryker in a report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and a consensus target price of $386.28.

View Our Latest Stock Analysis on SYK Stryker Stock Up 2.9% SYK opened at $331.32 on Friday. The business has a 50 day moving average of $329.10 and a 200-day moving average of $331.47. The stock has a market capitalization of $127.08 billion, a price-to-earnings ratio of 34.33, a P/E/G ratio of 2.05 and a beta of 0.76. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $396.86.

Stryker (NYSE:SYK – Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. During the same quarter in the previous year, the firm posted $3.13 EPS. The business’s revenue for the quarter was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, sell-side analysts anticipate that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Dividend Announcement The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

Insider Activity In other Stryker news, insider Dylan Bram Crotty sold 441 shares of Stryker stock in a transaction on Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the completion of the transaction, the insider owned 6,102 shares in the company, valued at approximately $2,005,178.22. The trade was a 6.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Ronda E. Stryker sold 300,000 shares of the business’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total value of $100,770,000.00. Following the completion of the transaction, the director directly owned 2,301,375 shares in the company, valued at approximately $773,031,862.50. This represents a 11.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 351,267 shares of company stock worth $118,197,701. Insiders own 4.60% of the company’s stock.

About Stryker (Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Recommended Stories Five stocks we like better than Stryker 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude? Okta Stock Surges 29%—Is $200 the Next Stop? Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

Key Takeaways SYK delivered 9% organic sales growth in Q2, with strength across MedSurg, Neurotechnology and Orthopaedics.Mako adoption is expanding, with more than 2.5 million procedures and launches in shoulders and RPS.Cybersecurity and supply disruptions remain risks, while temporary tariff benefits complicate margin gains. Stryker (SYK - Free Report) entered 2026 facing an unexpected cyber disruption, yet underlying demand, robotics adoption and international momentum remained strong. While a robust capital pipeline and active acquisition strategy support long-term growth, execution risks tied to recovery efforts, margin pressures and expanding exposure to new markets could shape the company’s performance over the coming quarters.

This Zacks Rank #3 (Hold) company’s shares have lost 6.7% so far this year compared with the industry’s 15.2% decline. The S&P 500 Index has appreciated 11.2% in the same time frame.

Stryker is a global leader in medical technology with a portfolio spanning Orthopaedics, MedSurg and Neurotechnology. The company has a market capitalization of $125.7 billion.

SYK’s bottom line is anticipated to improve 10.4% over the next five years. Its earnings beat estimates in three of the trailing four quarters and missed once, delivering a negative average surprise of 0.73%.

Image Source: Zacks Investment Research

Let’s delve deeper.

Factors Driving SYK’s ProspectsBroad-Based Organic Growth Demonstrates Strong Underlying Demand: Stryker delivered 9% organic sales growth in the second quarter of 2026, with both MedSurg & Neurotechnology and Orthopaedics posting high-single-digit growth. MedSurg & Neurotechnology increased 9.2%, led by strong performances in Instruments, Endoscopy and Medical, while Orthopaedics grew 8.6%. International sales also remained robust at 8.9%, supported by markets including Australia, Germany, Canada, India and Brazil. The breadth of growth is particularly encouraging because it indicates that demand remains resilient across multiple procedure categories rather than being concentrated in a single product franchise. This provides Stryker with a solid foundation for sustaining its 2026 growth outlook.

Mako Robotics Continues to Expand Competitive Advantage: Mako remains a critical growth engine for Stryker, with more than 2.5 million procedures performed globally and systems installed across 47 countries. U.S. knee sales increased 6.2%, supported by continued Mako adoption, while Ortho Tech grew 9.2% on robust Mako installations. The full commercial launch of Mako Shoulder and Mako RPS further expands the platform's addressable procedure base and strengthens Stryker's ability to compete across knees, hips and shoulders. As robotic-assisted surgery gains acceptance, the installed base should create recurring opportunities for implants, instruments and capital equipment, reinforcing Stryker's ecosystem-based competitive moat.

Margin Expansion and Cost Discipline Encouraging: Stryker's second-quarter performance showed meaningful operating leverage, with adjusted EPS rising 17.9% to $3.69. Adjusted gross margin expanded 60 basis points to 66%, and adjusted operating margin increased 170 basis points to 27.4%. Management attributed the improvement to favorable business mix, cost discipline and lower SG&A as a percentage of sales. This is important because the company continues to absorb costs associated with cybersecurity remediation and manufacturing recovery. Stronger margins suggest that Stryker's operational initiatives are offsetting some of these temporary expenses. If revenue momentum persists, incremental sales should increasingly flow through earnings, supporting management's full-year EPS outlook of $14.95-$15.10.

DownsidesCybersecurity Incident Continues to Impact Performance: Although Stryker has largely recovered from its cybersecurity incident, the event continues to weigh on 2026 financial performance. The disruption temporarily shut manufacturing facilities, resulting in lost production absorption and idle costs. Management also expects continued spending on cybersecurity remediation and stabilization throughout the year. The company acknowledged that these costs contribute to a wider EPS guidance range and could limit earnings conversion despite strong revenue growth. While production has been ramped and management believes the recovery is progressing, the episode demonstrates the vulnerability of a highly integrated global manufacturing network. Any additional disruption or slower-than-expected normalization could create further costs, supply constraints and pressure on margins.

Peripheral Vascular Supply Disruptions Are Limiting Near-Term Growth: Stryker's Peripheral Vascular business remains a significant near-term weakness following a supply disruption at a manufacturing facility supporting the Inari portfolio. The issue created a meaningful backlog and resulted in lost sales during the second quarter, offsetting otherwise strong U.S. growth. Management expects backorders to reach manageable levels by the end of the third quarter, but the disruption highlights execution risks within a strategically important growth market. Importantly, management estimated the shortfall was meaningful enough to potentially represent roughly 50-75 basis points of organic growth drag. Until production normalizes, Peripheral Vascular is likely to remain a constraint on consolidated growth despite favorable long-term market fundamentals.

Macro Headwinds Could Pressure Earnings: Stryker's second-quarter margin performance benefited from a net tariff benefit, making the underlying sustainability of margin expansion more complicated. Management noted ongoing pressure from oil and other raw materials while also highlighting continued cybersecurity-related expenses and broader macroeconomic uncertainty. Although the tariff benefit supported second-quarter gross margin, these favorable effects are not necessarily recurring, meaning future quarters could face less favorable comparisons. The company expects strong sales growth to provide earnings leverage, but higher input costs could absorb part of that benefit. Consequently, investors should distinguish between structural productivity gains and temporary cost benefits when assessing the durability of Stryker's 2026 margin trajectory.

Estimate TrendSYK has been witnessing a positive estimate revision trend for 2026. In the past 60 days, the Zacks Consensus Estimate for earnings has increased 3 cents to $15.02 per share.

The consensus mark for third-quarter 2026 revenues is pegged at $6.66 billion, indicating a 10% improvement from the year-ago reported actuals. The bottom-line estimate is pinned at $3.63, implying year-over-year growth of 13.8%.  

Stocks to ConsiderSome better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and The Cooper Companies (COO - Free Report) .

Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.

The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.

COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.

AlpenGlobal Capital LLC bought a new stake in Stryker Corporation (NYSE:SYK – Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 6,155 shares of the medical technology company’s stock, valued at approximately $1,938,000. Stryker makes up about 1.2% of AlpenGlobal Capital LLC’s investment portfolio, making the stock its 26th biggest position.

Several other hedge funds have also bought and sold shares of SYK. Norges Bank bought a new position in shares of Stryker in the 4th quarter worth $1,822,272,000. Auto Owners Insurance Co lifted its holdings in shares of Stryker by 35,047.0% during the 4th quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company’s stock worth $1,024,444,000 after acquiring an additional 2,906,448 shares during the last quarter. Flossbach Von Storch SE purchased a new position in Stryker in the second quarter worth $464,506,000. Wellington Management Group LLP grew its position in Stryker by 22.6% in the fourth quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock worth $2,282,192,000 after acquiring an additional 1,198,665 shares in the last quarter. Finally, Corient Private Wealth LLC increased its stake in Stryker by 104.4% in the second quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock valued at $887,525,000 after acquiring an additional 1,146,998 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth Several equities research analysts have issued reports on the company. Raymond James Financial set a $370.00 price target on Stryker in a research note on Friday, July 31st. Sanford C. Bernstein set a $410.00 price objective on Stryker in a research report on Friday, May 1st. BMO Capital Markets began coverage on Stryker in a report on Wednesday, July 8th. They set an “outperform” rating and a $369.00 price objective on the stock. Citizens Jmp dropped their target price on Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a research report on Monday, August 3rd. Finally, Robert W. Baird set a $385.00 target price on Stryker in a research note on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, Stryker has an average rating of “Moderate Buy” and a consensus price target of $386.28.

Get Our Latest Stock Analysis on Stryker Insider Activity In related news, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president owned 10,582 shares in the company, valued at $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Debra King sold 826 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the transaction, the insider directly owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 665,370 shares of company stock valued at $216,238,501. Corporate insiders own 4.60% of the company’s stock.

Stryker Stock Down 3.5% Shares of NYSE:SYK opened at $327.97 on Friday. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86. The company has a market cap of $125.80 billion, a PE ratio of 33.99, a P/E/G ratio of 2.17 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The stock’s 50-day moving average is $326.64 and its 200 day moving average is $332.66.

Stryker (NYSE:SYK – Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm’s revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the firm posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Sell-side analysts anticipate that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s payout ratio is presently 36.48%.

About Stryker (Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Featured Stories Five stocks we like better than Stryker 3 Energy Stocks Raising Dividends as the Sector Surges 5 Reasons the S&P 500 Could Keep Rallying Through Year-End Walmart’s Post-Earnings Drop Could Be a Buying Opportunity The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

August 05, 2026 09:34 ET  | Source: Stryker Corporation

Portage, Michigan, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable October 30, 2026, to shareholders of record at the close of business on September 30, 2026, representing an increase of 4.8% versus the prior year and unchanged from the previous quarter. 

About Stryker

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.

Contacts

For investor inquiries:
Nick Mead, Vice President, Investor Relations at 269-385-2600 or [email protected]   

For media inquiries:
Kim Montagnino, Vice President, Chief Communications Officer at 269-385-2600 or [email protected]

Portage, Michigan, July 30, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the second quarter of 2026:

Second Quarter Results

Reported net sales increased 9.4% to $6.6 billionOrganic net sales increased 9.0%Reported operating income margin of 25.2%Adjusted operating income margin(1) increased 170 bps to 27.4%Reported EPS increased 44.1% to $3.30Adjusted EPS(1) increased 17.9% to $3.69  Second Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology        9.7        %         0.5        %         9.2        %         —        %         9.2        %Orthopaedics        9.1                  0.4                  8.7                  0.1                  8.6         Total        9.4        %         0.4        %         9.0        %         —        %         9.0        % “We made significant progress in our recovery from the cyber incident, delivering strong growth in sales, earnings per share and operating cash flow in the second quarter,” said Kevin A. Lobo, Chair and CEO. “As we have seen in the past, the resilience of our teams when faced with challenges was once again on display. With our steady cadence of innovation and disciplined operational execution, we enter the second half of 2026 with regained momentum and remain confident in our ability to grow at the high end of MedTech.”

Sales Analysis

Consolidated net sales of $6.6 billion increased 9.4% in the quarter and 9.0% in constant currency. Organic net sales increased 9.0% in the quarter from increased unit volume.

MedSurg and Neurotechnology net sales of $3.6 billion increased 9.7% in the quarter and 9.2% in constant currency. Organic net sales increased 9.2% in the quarter including 9.1% from increased unit volume and 0.1% from higher prices.

Orthopaedics net sales of $3.0 billion increased 9.1% in the quarter and 8.7% in constant currency. Organic net sales increased 8.6% in the quarter from increased unit volume.

Earnings Analysis

Reported net earnings of $1.3 billion increased 44.3% in the quarter. Reported net earnings per diluted share of $3.30 increased 44.1% in the quarter. Reported gross profit margin and reported operating income margin were 68.3% and 25.2% in the quarter. Reported net earnings include certain items, such as charges for acquisition and integration-related activities, the amortization of purchased intangible assets, structural optimization and other special charges, goodwill and other impairments, costs to comply with certain medical device regulations, recall-related matters, regulatory and legal matters and tax matters. Excluding the aforementioned items, adjusted gross profit margin(1) was 66.0% in the quarter, and adjusted operating income margin(1) was 27.4% in the quarter. Adjusted net earnings(1) of $1.4 billion increased 17.6% in the quarter. Adjusted net earnings per diluted share(1) of $3.69 increased 17.9% in the quarter.

2026 Outlook

We are narrowing our full year 2026 guidance and now expect organic net sales growth(2) in the range of 8.3% to 9.3% and adjusted net earnings per diluted share(2) in the range of $14.95 to $15.10. Our sales guidance includes a modestly positive pricing impact. Additionally, foreign exchange is expected to have a slightly favorable impact on both sales and adjusted net earnings per diluted share(2) should rates hold near current levels.

(1) A reconciliation of the non-GAAP financial measures: adjusted gross profit margin, adjusted operating income and adjusted operating income margin, adjusted net earnings and adjusted net earnings per diluted share, to the most directly comparable GAAP measures: gross profit margin, operating income and operating income margin, net earnings and net earnings per diluted share, and other important information accompanies this press release.

(2) We are unable to present a quantitative reconciliation of our expected net sales growth to expected organic net sales growth as we are unable to predict with reasonable certainty and without unreasonable effort the impact and timing of acquisitions and divestitures and the impact of foreign currency exchange rates. We are unable to present a quantitative reconciliation of our expected net earnings per diluted share to expected adjusted net earnings per diluted share as we are unable to predict with reasonable certainty and without unreasonable effort the impact and timing of structural optimization and other special charges, acquisition-related expenses and the outcome of certain regulatory, legal and tax matters. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our Consolidated Statements of Earnings.

Conference Call on Thursday, July 30, 2026

As previously announced, we will host a conference call on Thursday, July 30, 2026 at 4:30 p.m., Eastern Time, to discuss our operating results for the quarter ended June 30, 2026 and provide an operational update.

Please register for this conference call at: https://stryker-2q2026-earnings.open-exchange.net. After registering, a confirmation will be sent via email, including dial-in details and unique conference call access codes required for call entry. Registration is open throughout the live call. To ensure you are connected prior to the beginning of the call, we suggest registering a minimum of 15 minutes before the start of the call.

A simultaneous webcast of the call will be accessible via the Investor Relations page of our website at www.stryker.com. For those not planning to ask a question of management, we recommend listening via the webcast. Please allow 15 minutes to register, download and install any necessary software.

Following the conference call, a replay will be available on our website up to one year from the time of the earnings call.

Caution Concerning Forward-Looking Statements

This press release contains information that includes or is based on forward-looking statements within the meaning of the federal securities law that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such risks and uncertainties include, but are not limited to: weakening of economic conditions, or the anticipation thereof, that could adversely affect the level of demand for our products; geopolitical risks, including from tariffs and the potential for further changes in trade policies and international conflicts, which have led to and could continue to lead to, among other things, increased market volatility; pricing pressures generally, including cost-containment measures that have adversely affected and could in the future adversely affect the price of or demand for our products; changes in foreign currency exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect approval of new products by the United States Food and Drug Administration and foreign regulatory agencies; inflationary pressures; increased interest rates or interest rate volatility; supply chain disruptions; changes in labor markets; changes in coverage and reimbursement levels from third-party payors; changes in the competitive environment; breaches, failures or other disruptions of our or our vendors’ or customers’ information technology systems or products resulting from cyber-attack, data leakage, unauthorized access or theft, including the cybersecurity incident first reported on March 11, 2026; a significant increase in product liability claims; the ultimate total cost with respect to recall-related and other regulatory and quality matters; the impact of investigative and legal proceedings and compliance risks; resolution of tax audits; changes in tax laws and regulations; the impact of legislation to reform the healthcare system in the United States or other countries; costs to comply with medical device regulations; changes in financial markets; changes in our credit ratings; our ability to integrate and realize the anticipated benefits of acquisitions in full or at all or within the expected timeframes; our ability to realize any anticipated cost savings; risks relating to climate change or other environmental, social and governance and sustainability related matters; and the impact on our operations and financial results of any public health emergency and any related policies and actions by governments or other third parties. Additional information concerning these and other factors is contained in our filings with the United States Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that affect the likelihood that actual results will differ from those contained in the forward-looking statements, except to the extent required by law.

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.

For investor inquiries:

Nick Mead, Vice President, Investor Relations at 269-385-2600 or [email protected]

For media inquiries:
Kim Montagnino, Vice President, Chief Communications Officer at 269-385-2600 or [email protected]

STRYKER CORPORATIONFor the Three and Six Months June 30(Unaudited - Millions of Dollars, Except Per Share Amounts)            CONSOLIDATED STATEMENTS OF EARNINGS         Three Months Six Months  2026   2025  % Change  2026   2025  % ChangeNet sales$        6,589          $        6,022                  9.4        % $        12,609          $        11,888                  6.1        %Cost of sales         2,091                   2,181                  (4.1)                  4,301                   4,303                  —         Gross profit$        4,498          $        3,841                  17.1        % $        8,308          $        7,585                  9.5        %% of sales         68.3        %          63.8        %            65.9        %          63.8        %  Research, development and engineering expenses         434                   407                  6.6                   847                   812                  4.3         Selling, general and administrative expenses         2,229                   2,079                  7.2                   4,510                   4,379                  3.0         Amortization of intangible assets         175                   187                  (6.4)                  355                   354                  0.3         Goodwill and other impairments         1                   55          nm          1                   90          nmTotal operating expenses$        2,839          $        2,728                  4.1        % $        5,713          $        5,635                  1.4        %Operating income$        1,659          $        1,113                  49.1        % $        2,595          $        1,950                  33.1        %% of sales         25.2        %          18.5        %            20.6        %          16.4        %  Other income (expense), net         (95)                  (97)                 (2.1)        %          (181)                  (170)                 6.5         Earnings before income taxes$        1,564          $        1,016                  53.9        % $        2,414          $        1,780                  35.6        %Income taxes         288                   132                  118.2                   393                   242                  62.4         Net earnings$        1,276          $        884                  44.3        % $        2,021          $        1,538                  31.4        %Net earnings per share of common stock:           Basic$        3.32          $        2.32                  43.1        % $        5.27          $        4.03                  30.8        %Diluted$        3.30          $        2.29                  44.1        % $        5.23          $        3.98                  31.4        %Weighted-average shares outstanding (in millions):           Basic 383.5   382.2     383.2   382.0   Diluted 386.0   386.4     386.2   386.4    CONDENSED CONSOLIDATED BALANCE SHEETS                  June 30        December 31   2026                       2025                       Assets   Cash and cash equivalents$        3,391         $        4,011        Marketable securities         85                  89        Accounts receivable, net         3,743                  4,039        Inventories         5,521                  5,310        Prepaid expenses and other current assets         1,678                  1,306        Total current assets$        14,418         $        14,755        Property, plant and equipment, net         3,958                  3,876        Goodwill and other intangibles, net         25,326                  24,972        Noncurrent deferred income tax assets         994                  1,098        Other noncurrent assets         3,234                  3,143        Total assets$        47,930         $        47,844        Liabilities and shareholders' equity   Current liabilities$        6,684         $        7,794        Long-term debt, excluding current maturities         14,192                  14,859        Income taxes         406                  402        Other noncurrent liabilities         2,660                  2,369        Shareholders' equity         23,988                  22,420        Total liabilities and shareholders' equity$        47,930         $        47,844         CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Six Months  2026           2025         Operating activities   Net earnings$        2,021          $        1,538         Depreciation         241                   214         Amortization of intangible assets         355                   354         Changes in operating assets, liabilities, income taxes payable and other, net         (775)                  (745)        Net cash provided by operating activities$        1,842          $        1,361         Investing activities   Acquisitions, net of cash acquired$        (459)         $        (4,814)        Proceeds/(Purchases) of short-term investments         —                   750         Purchases of property, plant and equipment         (368)                  (306)        Other investing, net         3                   130         Net cash used in investing activities$        (824)         $        (4,240)        Financing activities   Borrowings (payments) of debt, net$        (750)         $        2,331         Payments of dividends         (674)                  (641)        Other financing, net         (181)                  (145)        Net cash provided by (used in) financing activities$        (1,605)         $        1,545         Effect of exchange rate changes on cash and cash equivalents         (33)                  57         Change in cash and cash equivalents$        (620)         $        (1,277)         STRYKER CORPORATIONFor the Three and Six Months June 30(Unaudited - Millions of Dollars) SALES GROWTH ANALYSIS Three Months Six Months     Percentage Change     Percentage Change  2026  2025 As ReportedConstant Currency  2026  2025 As ReportedConstant CurrencyMedSurg and Neurotechnology:             Instruments             United States$        840         $        776                 8.4        %        8.4        % $        1,606         $        1,478                 8.7        %        8.7        %International         163                  142                 13.9                 12.3                   317                  278                 13.9                 9.6         Total$        1,003         $        918                 9.3        %        9.0        % $        1,923         $        1,756                 9.6        %        8.9        %Endoscopy             United States$        819         $        742                 10.2        %        10.2        % $        1,520         $        1,452                 4.6        %        4.6        %International         185                  157                 18.8                 16.5                   352                  314                 12.4                 8.1         Total$        1,004         $        899                 11.7        %        11.3        % $        1,872         $        1,766                 6.0        %        5.3        %Medical             United States$        945         $        840                 12.6        %        12.6        % $        1,692         $        1,642                 3.1        %        3.1        %International         177                  150                 17.9                 15.0                   332                  293                 13.2                 8.1         Total$        1,122         $        990                 13.4        %        13.0        % $        2,024         $        1,935                 4.6        %        3.9        %Vascular             United States$        250         $        268                 (6.7)        %        (6.7)        % $        530         $        471                 12.5        %        12.5        %International         246                  230                 6.3                 4.0                   483                  433                 11.3                 7.1         Total$        496         $        498                 (0.7)        %        (1.8)        % $        1,013         $        904                 11.9        %        9.9        %MedSurg and Neurotechnology             United States$        2,854         $        2,626                 8.7        %        8.7        % $        5,348         $        5,043                 6.1        %        6.1        %International         771                  679                 13.3                 11.1                   1,484                  1,318                 12.5                 8.1         Total$        3,625         $        3,305                 9.7        %        9.2        % $        6,832         $        6,361                 7.4        %        6.5        %              Orthopaedics:             Knees             United States$        488         $        460                 6.2        %        6.2        % $        960         $        924                 3.8        %        3.8        %International         205                  180                 14.0                 12.4                   403                  355                 13.7                 9.2         Total$        693         $        640                 8.4        %        8.0        % $        1,363         $        1,279                 6.6        %        5.3        %Hips             United States$        296         $        283                 4.9        %        4.9        % $        572         $        552                 3.6        %        3.6        %International         183                  183                 —                 (0.8)                  367                  357                 2.9                 (0.6)        Total$        479         $        466                 2.9        %        2.6        % $        939         $        909                 3.3        %        1.9        %Trauma and Extremities             United States$        791         $        702                 12.5        %        12.5        % $        1,558         $        1,415                 10.1        %        10.1        %International         281                  255                 10.3                 8.5                   549                  487                 12.7                 7.7         Total$        1,072         $        957                 11.9        %        11.5        % $        2,107         $        1,902                 10.7        %        9.4        %Ortho Tech             United States$        530         $        483                 9.5        %        9.5        % $        997         $        942                 5.8        %        5.8        %International         187                  166                 12.8                 11.8                   366                  324                 12.9                 9.2         Total$        717         $        649                 10.3        %        10.0        % $        1,363         $        1,266                 7.6        %        6.7        % $        2,961         $        2,712                 9.2        %        8.8        % $        5,772         $        5,356                 7.7        %        6.5        %Spinal Implants             United States$        —         $        —                 (100.0)        %        (100.0)        % $        —         $        118                 (100.0)        %        (100.0)        %International         3                  5                 (36.7)                (40.9)                  5                  53                 (90.2)                (91.2)        Total$        3         $        5                 (36.7)        %        (40.9)        % $        5         $        171                 (96.9)        %        (97.1)        %Orthopaedics             United States$        2,105         $        1,928                 9.1        %        9.1        % $        4,087         $        3,951                 3.4        %        3.4        %International         859                  789                 8.9                 7.6                   1,690                  1,576                 7.2                 3.0         Total$        2,964         $        2,717                 9.1        %        8.7        % $        5,777         $        5,527                 4.5        %        3.3        %              Geographic:             United States$        4,959         $        4,554                 8.9        %        8.9        % $        9,435         $        8,994                 4.9        %        4.9        %International         1,630                  1,468                 11.0                 9.2                   3,174                  2,894                 9.7                 5.3         Total$        6,589         $        6,022                 9.4        %        9.0        % $        12,609         $        11,888                 6.1        %        5.0        % Note: In the first quarter 2026 we announced a change in our organizational structure. Our new Ortho Tech business combines the orthopaedic instruments portfolio (Orthopaedic Instruments) from Instruments with Other Orthopaedics. In addition, Neuro Cranial and the spine enabling technologies portfolio (Enabling Technologies) from Other Orthopaedics were combined with the remaining Instruments business to align with our internal reporting structure. Ortho Tech includes sales related to Orthopaedic Instruments of $523 and $501 and Other Orthopaedics of $194 and $148 for the three months 2026 and 2025. For the six months 2026 and 2025 Ortho Tech includes sales related to Orthopaedic Instruments of $1,012 and $985 and Other Orthopaedics of $351 and $281. Instruments includes sales related to Neuro Cranial of $681 and $616 and Enabling Technologies of $28 and $34 for the three months 2026 and 2025. For the six months 2026 and 2025 Instruments includes sales related to Neuro Cranial of $1,287 and $1,179 and Enabling Technologies of $54 and $63. We have reflected these changes in all historical periods presented.

SUPPLEMENTAL INFORMATION - RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

We supplement the reporting of our financial information determined under accounting principles generally accepted in the United States (GAAP) with certain non-GAAP financial measures, including: percentage sales growth in constant currency; percentage organic sales growth; adjusted gross profit; adjusted selling, general and administrative expenses; adjusted research, development and engineering expenses; adjusted operating income; adjusted other income (expense), net; adjusted income taxes; adjusted effective income tax rate; adjusted net earnings; and adjusted net earnings per diluted share (Diluted EPS). We believe these non-GAAP financial measures provide meaningful information to assist investors and shareholders in understanding our financial results and assessing our prospects for future performance. Management believes percentage sales growth in constant currency and the other adjusted measures described above are important indicators of our operations because they exclude items that may not be indicative of or are unrelated to our core operating results and provide a baseline for analyzing trends in our underlying businesses. Management uses these non-GAAP financial measures for reviewing the operating results of reportable business segments and analyzing potential future business trends in connection with our budget process and bases certain management incentive compensation on these non-GAAP financial measures.

To measure percentage sales growth in constant currency, we remove the impact of changes in foreign currency exchange rates that affect the comparability and trend of sales. Percentage sales growth in constant currency is calculated by translating current and prior year results at the same foreign currency exchange rate. To measure percentage organic sales growth, we remove the impact of changes in foreign currency exchange rates, acquisitions and divestitures, which affect the comparability and trend of sales. Percentage organic sales growth is calculated by translating current year and prior year results at the same foreign currency exchange rates excluding the impact of acquisitions and divestitures. To measure earnings performance on a consistent and comparable basis, we exclude certain items that affect the comparability of operating results and the trend of earnings. The income tax effect of each adjustment was determined based on the tax effect of the jurisdiction in which the related pre-tax adjustment was recorded. These adjustments are irregular in timing and may not be indicative of our past and future performance.

Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for reported sales growth, gross profit, selling, general and administrative expenses, research, development and engineering expenses, operating income, other income (expense), net, income taxes, effective income tax rate, net earnings and net earnings per diluted share, the most directly comparable GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of our operations that, when viewed with our GAAP results and the reconciliations to corresponding GAAP financial measures below, provide a more complete understanding of our business. We strongly encourage investors and shareholders to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.

The following reconciles the non-GAAP financial measures discussed above with the most directly comparable GAAP financial measures. The weighted-average diluted shares outstanding used in the calculation of adjusted net earnings per diluted share are the same as those used in the calculation of reported net earnings per diluted share for the respective period.

STRYKER CORPORATIONFor the Three and Six Months June 30(Unaudited - Millions of Dollars, Except Per Share Amounts)          Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial MeasuresThree Months 2026Gross ProfitSelling, General & Administrative ExpensesResearch, Development & Engineering ExpensesOperating IncomeOther Income (Expense), NetIncome TaxesNet EarningsEffective
Tax RateDiluted EPSReported$        4,498         $        2,229         $        434         $        1,659         $     (95)          $        288         $        1,276                 18.4        %$        3.30         Reported percent net sales         68.3        %         33.8        %         6.6        %         25.2        %        (1.4)        %nm         19.4        %  Acquisition and integration-related costs:         Inventory stepped-up to fair value         —                  —                  —                  —                  —                  —                  —                 —                  —         Other acquisition and integration-related (a)         7                  (14)                 (4)                 25                  —                  3                  22                 —                  0.06         Amortization of purchased intangible assets         —                  —                  —                  175                  —                  33                  142                 0.3                  0.37         Structural optimization and other special charges (b)         5                  (89)                 (1)                 95                  (6)                 20                  69                 0.3                  0.18         Goodwill and other impairments (c)         —                  —                  —                  1                  —                  —                  1                 —                  —         Medical device regulations (d)         —                  —                  (5)                 5                  —                  1                  4                 —                  0.01         Recall-related matters (e)         (1)                  (3)                 —                  2                  —                  1                  1                 —                  —         Regulatory and legal matters (f)         —                  (3)                 —                  3                  —                  —                  3                 —                  —         Tax matters (g)         —                  —                  —                  —                  —                  (39)                 39                (2.5)                  0.11         Reversal of 2025 tariffs         (158)                 —                  —                  (158)                 —                  (25)                 (133)               —               (0.34)        Adjusted$        4,351         $        2,120         $        424         $        1,807         $      (101)       $        282         $        1,424                 16.5        %$        3.69         Adjusted percent net sales         66.0        %         32.2        %         6.4        %         27.4        %        (1.5)        %nm         21.6        %   Three Months 2025Gross ProfitSelling, General & Administrative ExpensesResearch, Development & Engineering ExpensesOperating IncomeOther Income (Expense), NetIncome TaxesNet EarningsEffective
Tax RateDiluted EPSReported$        3,841         $        2,079         $        407         $        1,113         $        (97)         $        132         $        884                 13.0        %$        2.29        Reported percent net sales         63.8        %         34.5        %         6.8        %         18.5        %        (1.6)        %nm         14.7        %  Acquisition and integration-related costs:         Inventory stepped-up to fair value         65                  —                  —                  65                  —                  16                  49                 0.5                  0.12        Other acquisition and integration-related (a)         1                  (76)                  (1)                 78                  —                  20                  58                 0.7                  0.15        Amortization of purchased intangible assets         —                  —                  —                  187                  —                  39                  148                 1.0                  0.37        Structural optimization and other special charges (b)         6                  (2)                  (3)                  11                  (9)                  (2)                 4              (0.2)                  0.01        Goodwill and other impairments (c)         —                  —                  —                  55                  —                  22                  33                 1.2                  0.10        Medical device regulations (d)         —                  —                  (7)                  7                  —                  1                  6                 0.1                  0.02        Recall-related matters (e)         21                  (1)                  —                  22                  —                  1                  21               (0.3)                 0.06        Regulatory and legal matters (f)         —                  (7)                  —                  7                  —                  1                  6                 0.1                  0.01        Tax matters (g)         —                  —                  —                  —                  —                  (2)                 2               (0.2)                 —        Adjusted$        3,934         $        1,993         $        396         $        1,545         $        (106)       $        228         $        1,211                 15.9        %$        3.13        Adjusted percent net sales         65.4        %         33.1        %         6.6        %         25.7        %        (1.8)        %nm         20.1        %   nm - not meaningful

(a) Charges represent certain acquisition and integration-related costs associated with acquisitions, including:

 Three Months  2026           2025        Termination of sales relationships$        6          $        —        Employee retention and workforce reductions         (3)                  29        Changes in the fair value of contingent consideration         6                   3        Manufacturing integration costs         5                   3        Other integration-related activities (e.g., deal costs and legal entity rationalization)         11                   43        Adjustments to Operating Income $        25          $        78        Adjustments to Income Taxes$        3          $        20        Adjustments to Net Earnings$        22          $        58         (b) Structural optimization and other special charges represent the costs associated with:

 Three Months  2026           2025         Employee retention and workforce reductions$        6          $        5         Closure/transfer of manufacturing and other facilities (e.g., site closure, contract termination and redundant employee costs)         4                   7         Product line exits         9                   (10)        Termination of sales relationships in certain countries         6                   (3)        Other charges         70                   12         Adjustments to Operating Income $        95          $        11         Adjustments to Other Income (Expense), Net$        (6)         $        (9)        Adjustments to Income Taxes$        20          $        (2)        Adjustments to Net Earnings$        69          $        4          (c) Goodwill and other impairments represent the costs associated with:

 Three Months  2026         2025       Certain long-lived and intangible asset write-offs and impairments$        —         $        52        Product line exits (e.g., long-lived asset and specifically-identified intangible asset write-offs)         1                  3        Adjustments to Operating Income$        1         $        55        Adjustments to Income Taxes$        —         $        22        Adjustments to Net Earnings$        1         $        33         (d) Charges represent the costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with the medical device reporting regulations and other requirements of the new medical device regulations in the European Union.
(e) Charges represent changes in our best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within a range is not known, to resolve certain recall-related matters.
(f) Charges represent changes in our best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within a range is not known, to resolve certain regulatory or other legal matters and the amount of favorable awards from settlements.
(g) Benefits / (charges) represent the accounting impact of certain significant and discrete tax items, including:

 Three Months  2026    2025 Adjustments related to the transfer of certain intellectual properties between tax jurisdictions$        (55)  $        (45)  Other tax matters 16    43   Adjustments to Income Taxes$        (39)  $        (2)  Adjustments to Other Income (Expense), Net$        —   $        —  Adjustments to Net Earnings$        39   $        2    Six Months 2026Gross ProfitSelling, General & Administrative ExpensesResearch, Development & Engineering ExpensesOperating IncomeOther Income (Expense), NetIncome TaxesNet EarningsEffective
Tax RateDiluted EPSReported$        8,308         $        4,510         $        847         $        2,595         $        (181)         $        393         $        2,021                 16.3        %$        5.23         Reported percent net sales         65.9        %         35.8        %         6.7        %         20.6        %        (1.4)        %nm         16.0        %  Acquisition and integration-related costs:         Inventory stepped-up to fair value         —                  —                  —                  —                  —                  —                  —                 —                  —         Other acquisition and integration-related (a)         9                  (27)                 (8)                 44                  —                  7                  37                 —                  0.10         Amortization of purchased intangible assets         —                  —                  —                  355                  —                  63                  292                 0.3                  0.75         Structural optimization and other special charges (b)         19                  (193)                 (1)                 213                  (17)                 45                  151                 0.6                  0.39         Goodwill and other impairments (c)         —                  —                  —                  1                  —                  —                  1                 —                  —         Medical device regulations (d)         —                  —                (10)                  10                  —                  2                  8                 —                  0.02         Recall-related matters (e)         —                  (12)                 —                  12                  —                  3                  9                 —                  0.02         Regulatory and legal matters (f)         —                  (6)                 —                  6                  —                  1                  5                 —                  0.01         Tax matters (g)         —                  —                  —                  —                  —                  (37)                 37               (1.5)                  0.11         Reversal of 2025 tariffs         (158)                 —                  —                  (158)                 —                  (25)                 (133)                —                (0.34)        Adjusted$        8,178         $        4,272         $        828         $        3,078         $        (198)        $        452         $        2,428                 15.7        %$        6.29         Adjusted percent net sales         64.9        %         33.9        %         6.6        %         24.4        %        (1.6)        %nm         19.3        %   Six Months 2025Gross ProfitSelling, General & Administrative ExpensesResearch, Development & Engineering ExpensesOperating IncomeOther Income (Expense), NetIncome TaxesNet EarningsEffective
Tax RateDiluted EPSReported$        7,585         $        4,379         $        812         $        1,950         $     (170)          $        242         $        1,538                 13.6        %$        3.98        Reported percent net sales         63.8        %         36.8        %         6.8        %         16.4        %        (1.4)        %nm         12.9        %  Acquisition and integration-related costs:         Inventory stepped-up to fair value         99                  —                  —                  99                  —                  24                  75                 0.5                  0.19        Other acquisition and integration-related (a)         14                  (247)                 (2)                 263                  —                  26                  237              (0.7)                  0.62        Amortization of purchased intangible assets         —                  —                  —                  354                  —                  73                  281                 1.1                  0.72        Structural optimization and other special charges (b)         28                  (21)                 (3)                 52                  (9)                 12                  31                 0.3                  0.08        Goodwill and other impairments (c)         —                  —                  —                  90                  —                  31                  59                 1.0                  0.16        Medical device regulations (d)         1                  —               (18)                 19                  —                  4                  15                 0.1                  0.04        Recall-related matters (e)         52                  (3)                 —                  55                  —                  9                  46                 0.1                  0.12        Regulatory and legal matters (f)         —                  (7)                 —                  7                  —                  2                  5                 0.1                  0.01        Tax matters (g)         —                  —                  —                  —                  —                  (21)                 21              (1.2)                 0.05        Adjusted$        7,779         $        4,101         $        789         $        2,889         $       (179)       $        402         $        2,308                 14.9        %$        5.97        Adjusted percent net sales         65.4        %         34.5        %         6.6        %         24.3        %        (1.5)        %nm         19.4        %   (a) Charges represent certain acquisition and integration-related costs associated with acquisitions, including:

 Six Months  2026          2025        Termination of sales relationships$        6         $        —        Employee retention and workforce reductions         —                  45        Changes in the fair value of contingent consideration         9                  1        Manufacturing integration costs         10                  7        Stock compensation payments upon a change in control         —                  139        Other integration-related activities (e.g., deal costs and legal entity rationalization)         19                  71        Adjustments to Operating Income $        44         $        263        Adjustments to Income Taxes$        7         $        26        Adjustments to Net Earnings$        37         $        237         (b) Structural optimization and other special charges represent the costs associated with:

 Six Months  2026           2025         Employee retention and workforce reductions$        13          $        38         Closure/transfer of manufacturing and other facilities (e.g., site closure, contract termination and redundant employee costs)         9                   12         Product line exits (e.g., inventory, long-lived asset and specifically-identified intangible asset write-offs)         11                   (7)        Termination of sales relationships in certain countries         87                   (4)        Other charges         93                   13         Adjustments to Operating Income $        213          $        52         Adjustments to Other Income (Expense), Net$        (17)         $        (9)        Adjustments to Income Taxes$        45          $        12         Adjustments to Net Earnings$        151          $        31          (c) Goodwill and other impairments represent the costs associated with:

 Six Months  2026         2025        Certain long-lived and intangible asset write-offs and impairments$        —         $        86        Product line exits (e.g., long-lived asset and specifically-identified intangible asset write-offs)         1                  4        Adjustments to Operating Income$        1         $        90        Adjustments to Income Taxes$        —         $        31        Adjustments to Net Earnings$        1         $        59         (d) Charges represent the costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with the medical device reporting regulations and other requirements of the new medical device regulations in the European Union.
(e) Charges represent changes in our best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within a range is not known, to resolve certain recall-related matters.
(f) Charges represent changes in our best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within a range is not known, to resolve certain regulatory or other legal matters and the amount of favorable awards from settlements.
(g) Benefits / (charges) represent the accounting impact of certain significant and discrete tax items, including:

 Six Months  2026    2025  Adjustments related to the transfer of certain intellectual properties between tax jurisdictions$        (75)   $        (92)  Other tax matters 38     71   Adjustments to Income Taxes$        (37)   $        (21)  Adjustments to Other Income (Expense), Net$        —    $        —   Adjustments to Net Earnings$        37    $        21   

New handheld robotic technology expands the Mako platform and brings Mako robotic-assisted knee replacement to a new segment of the orthopaedic market

Stryker announced the U.S. commercial launch of Mako RPS (Robotic Power System) for total knee replacement procedures. The launch introduces Mako Handheld Robotics, expanding the Mako portfolio beyond robotic-arm assisted surgery. Mako RPS combines robotic execution, intraoperative planning and a familiar handheld power tool workflow. , /PRNewswire/ -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today the U.S. commercial launch of Mako RPS® (Robotic Power System) for total knee replacement procedures, further expanding the Mako portfolio into a new category of orthopaedic robotics.

Mako RPS® (Robotic Power System)

Mako RPS® (Robotic Power System) The launch marks the introduction of the Mako Handheld Robotics platform, alongside the Mako SmartRobotics™ with Mako 4, Stryker's multi-specialty robotic-arm assisted platform. Designed to provide surgeons with an intuitive handheld robotic experience, Mako RPS combines Stryker's expertise in robotics and power tools to bring robotic technology to a new customer segment of the orthopaedic market.

"Customer response during the limited market release has been exceptionally strong," said Keith Evans, VP/GM of Stryker's Mako and Enabling Technologies business. "As we expand the Mako portfolio, we're proud to set a new standard for what customers can expect from a handheld robotics technology – bringing together robotics, power tool expertise and a deep understanding of surgical workflows."

As healthcare providers increasingly seek flexibility in how robotic technology is incorporated into orthopaedic procedures, Mako RPS offers a new option that blends robotic execution with a familiar surgical experience. The launch expands access to Mako, offering surgeons more robotic options and bringing Mako to a broader range of customers and care settings.

Compatible with Stryker's clinically proven1-2 Triathlon® Total Knee System, Mako RPS for Total Knee features intraoperative planning and a robotically enabled saw equipped with Stryker's patented active adjustment technology, which responds to a surgeon's hand movements and helps maintain alignment with the surgical plan in real time. The system provides a familiar cutting experience without the need for cutting blocks, offering an option for surgeons interested in adopting robotic technology while integrating easily into their existing surgical workflows.

"By combining robotic technology with the clinically proven Triathlon® Total Knee System, Mako RPS delivers an intuitive surgical experience that builds on the implant and workflow familiarity surgeons know and trust2-3," said Lisa Kloes, vice president and general manager of Stryker's Knee business.

Built to work with Stryker's multi-specialty Q Guidance System, Mako RPS expands Stryker's ecosystem of enabling technologies across the continuum of orthopaedic care and sites of service.

For more than two decades, Mako has defined orthopaedic robotics worldwide. With more than 2.5 million procedures performed in 47 countries, Mako continues to advance the adoption of robotics in orthopaedics and support surgeons in delivering personalized patient care.

About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.

Media contact
Stryker
Jenny Braga
Senior Director, External Affairs
[email protected]

References:

American Joint Replacement Registry (AJRR): 2025 Annual Report. Rosemont, IL: American Academy of Orthopaedic Surgeons (AAOS), 2025. Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR). Hip, Knee & Shoulder Arthroplasty Annual Report 2025. AOA;2025. https://aoanjrr.sahmri.com/. Accessed 11 Oct. 2025 Scott CEH, Snowden GT, Cawley W, et al. Fifteen-year prospective longitudinal cohort study of outcomes following single radius total knee arthroplasty. Bone Jt Open. 2023;4(10):808-816. Published 2023 Oct 24.doi:10.1302/2633-1462.410.BJO-2023-0086.R1 SOURCE Stryker